BFM
IPCI

Boothbay Fund Management’s Intellipharmaceuticals International Inc. IPCI Stock Holding History

Boothbay Fund Management’s Portfolio IPCI Stock Details IPCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,720
Closed -$17K – 1029
2018
Q2 		$17K Buy
+3,720
New +$16.9K ﹤0.01% 725

Other funds holding IPCI

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
FANJ
Financial Architects (New Jersey) Marlton, New Jersey $663M AUM 15.53% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Boothbay Fund Management's IPCI Position: Q3 2018 in Review

Boothbay Fund Management sold out of Intellipharmaceuticals International Inc. (IPCI) in Q3 2018, closing a stake of 3,720 shares — an estimated $17K sold.

Boothbay Fund Management first reported a position in IPCI in Q2 2018 and held it in 1 quarter. The position peaked at $17K in Q2 2018. 10 funds tracked by Wall St. Rank hold IPCI as of Q3 2018.

  • Boothbay Fund Management reported no remaining Intellipharmaceuticals International Inc. position as of Q3 2018 after selling out during the quarter.
  • Boothbay Fund Management sold 3,720 Intellipharmaceuticals International Inc. shares in Q3 2018, an estimated $17K.
  • Boothbay Fund Management first reported a position in Intellipharmaceuticals International Inc. in Q2 2018 and held it in 1 quarter.
  • Boothbay Fund Management's Intellipharmaceuticals International Inc. position peaked at $17K in Q2 2018.
  • 10 funds tracked by Wall St. Rank held Intellipharmaceuticals International Inc. as of Q3 2018.

Based on Boothbay Fund Management's 13F filing for Q3 2018, filed 14 Nov 2018.